Elite in Fabry Disease

Kathy M. Nicholls

Melbourne, VIC, AU 
Elite in Fabry Disease
Melbourne, VIC, AU 
OverviewLocationsClinical Research

Overview

Kathy Nicholls practices in Melbourne, Australia. Ms. Nicholls is rated as an Elite expert by MediFind in the treatment of Fabry Disease. Her top areas of expertise are Fabry Disease, Polycystic Kidney Disease, Farber Lipogranulomatosis, Gaucher Disease, and Kidney Transplant.

Her clinical research consists of co-authoring 29 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 23 articles and participated in 3 clinical trials in the study of Fabry Disease.

Gender
Female

Locations

Melbourne, VIC, Australia
Other Locations
Parkville, VIC, Australia
Clayton, VIC, Australia
Parkville, NSW, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drug: Mezagitamab
Study Phase: Phase 1
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
Enrollment Status: Terminated
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Replagal
Study Phase: Phase 3
An Open-Label, Multinational Study Of The Efficacy And Safety of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease
An Open-Label, Multinational Study Of The Efficacy And Safety of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Drug
Study Drug: AVR-RD-01
Study Phase: Phase 1/Phase 2
Complement Activation in the Lysosomal Storage Disorders
Complement Activation in the Lysosomal Storage Disorders
Enrollment Status: Withdrawn
Publish Date: June 07, 2021
Intervention Type: Diagnostic test
View 3 Less Clinical Trials

29 Total Publications

Enhancing diagnostic outcomes in kidney genetic disorders: the KidGen national kidney genomics study protocol.
Enhancing diagnostic outcomes in kidney genetic disorders: the KidGen national kidney genomics study protocol.
Journal: BMC nephrology
Published: December 14, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Nicholls's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile